Literature DB >> 15221281

No relationship of -627 interleukin-10 promoter polymorphism in Chinese patients with rheumatoid arthritis.

Chung-Ming Huang1, Chang-Hai Tsai, Chi-Lan Chen, Chin-Ping Chang, Fuu-Jen Tsai.   

Abstract

The aim of this study was to examine whether -627 interleukin-10 (IL-10) promoter polymorphism is a marker of susceptibility to or severity of rheumatoid arthritis (RA) in Chinese patients in Taiwan. The study included 198 Chinese patients with RA. One hundred unrelated healthy individuals living in central Taiwan served as the control subjects. The relationship between IL-10 gene polymorphism and clinical manifestations of RA was evaluated. For the genotype, allelic frequency, and carriage rate of IL-10 polymorphism, there were no statistically significant differences found between patients and controls. Furthermore, we did not detect any association of IL-10 genotype with rheumatoid factor (RF), extra-articular involvement, or bone erosion in the RA patients. The lack of association of -627 IL-10 gene polymorphism with RA and the clinical findings in our study implies that the IL-10 gene polymorphism cannot serve as a candidate gene marker for screening RA patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221281     DOI: 10.1007/s00296-004-0480-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  27 in total

1.  Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline.

Authors:  J Bienvenu; C Doche; M C Gutowski; M Lenoble; A Lepape; J P Perdrix
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

Review 2.  Biological properties of interleukin 10.

Authors:  M Howard; A O'Garra; H Ishida; R de Waal Malefyt; J de Vries
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

Review 3.  Rheumatoid arthritis. Pathophysiology and implications for therapy.

Authors:  E D Harris
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

4.  Haplotype associated with low interleukin-10 production in patients with severe asthma.

Authors:  S Lim; E Crawley; P Woo; P J Barnes
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

5.  IL-10 gene promoter polymorphisms in rheumatoid arthritis.

Authors:  A H Hajeer; M Lazarus; D Turner; R A Mageed; J Vencovsky; P Sinnott; I V Hutchinson; W E Ollier
Journal:  Scand J Rheumatol       Date:  1998       Impact factor: 3.641

6.  Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease.

Authors:  J Grove; A K Daly; M F Bassendine; E Gilvarry; C P Day
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

7.  HLA-DRB1 genotyping in patients with rheumatoid arthritis in Taiwan.

Authors:  J H Yen; J R Chen; W J Tsai; J J Tsai; H W Liu
Journal:  J Rheumatol       Date:  1995-08       Impact factor: 4.666

8.  Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnically diverse populations.

Authors:  K MacKay; A Milicic; D Lee; M Tikly; S Laval; J Shatford; P Wordsworth
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

9.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

10.  Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.

Authors:  A D'Andrea; M Aste-Amezaga; N M Valiante; X Ma; M Kubin; G Trinchieri
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.